Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sinocelltech Group's share price for the quarter that ended in Mar. 2026 was ¥40.32. Sinocelltech Group's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 470 Mil. Therefore, Sinocelltech Group's market cap for the quarter that ended in Mar. 2026 was ¥18,964 Mil.
Sinocelltech Group's quarterly market cap
declined
from Sep. 2025 (¥24,850 Mil) to Dec. 2025 (¥19,288 Mil) and
declined
from Dec. 2025 (¥19,288 Mil) to Mar. 2026 (¥18,964 Mil).
Sinocelltech Group's annual market cap
declined
from Dec. 2023 (¥23,990 Mil) to Dec. 2024 (¥16,135 Mil) but then
increased
from Dec. 2024 (¥16,135 Mil) to Dec. 2025 (¥19,288 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sinocelltech Group's Enterprise Value for Today is ¥18,331 Mil.
Sinocelltech Group (SHSE:688520) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sinocelltech Group Market Cap Related Terms
Sinocelltech Group Market Cap Historical Data
* Premium members only.
The historical data trend for Sinocelltech Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688520 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Sinocelltech Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinocelltech Group Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinocelltech Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Sinocelltech Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sinocelltech Group's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinocelltech Group (SHSE:688520) has a Market Cap of ¥16,532 Mil as of Jul. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sinocelltech Group and its competitors. According to the industry distribution chart, Sinocelltech Group ranks #134 out of 1423 companies in the Biotechnology industry, placing it in the top 9.4%.
Is Sinocelltech Group's Market Cap too high?
Sinocelltech Group's current Market Cap is ¥16,532 Mil. Based on the distribution chart, Sinocelltech Group ranks #134 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sinocelltech Group has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinocelltech Group's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinocelltech Group ranks #134 out of 1423 companies for Market Cap. This places Sinocelltech Group in the top 9% of its industry — outperforming the majority of peers. The industry median Market Cap is 112.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.15, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sinocelltech Group and its competitors. For the Biotechnology industry, the median Market Cap is 112.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinocelltech Group's current Market Cap is ¥16,532 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinocelltech Group stock overvalued right now?
Based on GuruFocus' analysis, Sinocelltech Group (SHSE:688520) is currently considered Fairly Valued. The stock's GF Value™ is ¥36.51, compared to a current price of ¥35.15 — trading 3.7% below its estimated fair value. The current Market Cap is ¥16,532 Mil. Sinocelltech Group's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sinocelltech Group (SHSE:688520), the current Market Cap is ¥16,532 Mil as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinocelltech Group (SHSE:688520) Overvalued in 2026?
Based on GuruFocus' analysis, Sinocelltech Group stock appears to be undervalued.
The current stock price of ¥35.15 is trading 3.7% below its estimated GF Value™ of ¥36.51.
GuruFocus considers Sinocelltech Group to be Fairly Valued.
Key valuation signals for SHSE:688520:
Market Cap: ¥16,532 Mil
GF Value™: ¥36.51 vs. price of ¥35.15 (3.7% below fair value)
No single metric tells the full story. See the SHSE:688520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinocelltech Group Ltd is one of Chin's biopharma companies specializing in biologics and vaccines. The company's therapeutic areas include oncology, immunology and inflammation, ophthalmology, and prophylactic vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. The capabilities of the company include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up, protein purification development, and large scale production.
54GF Score
Get the complete analysis for SHSE:688520
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688520 has been successfully added to your 
